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Background: An important inter-individual variability in the response of insulin sensitivity following a fish oil
supplementation has been observed. The objective was to examine the associations between single nucleotide
polymorphisms (SNPs) within sterol regulatory element binding transcription factor 1 (SREBF1) gene and the response
of insulin sensitivity to a fish oil supplementation.
Methods: Participants (n = 210) were recruited in the greater Quebec City area and followed a 6-week fish oil
supplementation protocol (5 g/day: 1.9-2.2 g EPA; 1.1 g DHA). Insulin sensitivity was assessed by the quantitative
insulin sensitivity check index (QUICKI). Three tag SNPs (tSNPs) within SREBF1 gene were genotyped according to
TAQMAN methodology.
Results: Three tSNPs (rs12953299, rs4925118 and rs4925115) covered 100% of the known genetic variability within
SREBF1 gene. None of the three tSNPs was associated with either baseline fasting insulin concentrations (rs12953299,
rs4925118 and rs4925115) (p = 0.29, p = 0.20 and p = 0.70, respectively) or QUICKI (p = 0.20, p = 0.18 and p = 0.76,
respectively). The three tSNPs (rs12953299, rs4925118 and rs4925115) were associated with differences in the response
of plasma insulin levels (p = 0.01, p = 0.005 and p = 0.004, respectively) and rs12953299 as well as rs4925115 were
associated with the insulin sensitivity response (p = 0.009 and p = 0.01, respectively) to the fish oil supplementation,
independently of the effects of age, sex and BMI.
Conclusions: The genetic variability within SREBF1 gene has an impact on the insulin sensitivity in response to a fish
oil supplementation.
Trial registration: clinicaltrials.gov: NCT01343342.
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The sterol regulatory element binding transcription factor
1 (SREBF1) gene encodes a transcription factor which is a
main regulator of lipid metabolism, the sterol regulatory
element-binding protein-1c (SREBP-1c) [1]. SREBF1 gene
is expressed in multiple tissues including liver, white and
brown adipose tissue, adrenal gland and to a lower extent
in pancreatic β-cell [2,3]. Insulin induces the expression of
the SREBF1 gene in adipose tissue, liver and muscle cells
[1]. However, in pancreatic β-cell, it has been observed* Correspondence: marie-claude.vohl@fsaa.ulaval.ca
1Institute of Nutrition and Functional Foods (INAF), Laval University, 2440
Hochelaga Blvd., Quebec G1V 0A6, Canada
2Department of Food Science and Nutrition, Laval University, 2425 de
l’Agriculture St., Quebec G1K 7P4, Canada
Full list of author information is available at the end of the article
© 2014 Bouchard-Mercier et al.; licensee BioM
Creative Commons Attribution License (http:/
distribution, and reproduction in any medium
Domain Dedication waiver (http://creativecom
article, unless otherwise stated.that SREBP-1c modulates insulin secretion potentially
through a mechanism involving lipotoxicity [3,4]. SREBP-
1c may be involved in reticulum endoplasmic stress and
in β-cell apoptosis [5]. The knockdown of SREBP-1c in
pancreatic β-cell inhibited the expression of markers of
reticulum endoplasmic stress [5].
SREBF1 gene expression is also regulated by dietary
intakes. For example, an insulin independent effect has
been demonstrated with different types of sugar such as
glucose, fructose and sucrose, on SREBF1 gene expression
induction [6]. Dietary fats also affect SREBF1 gene expres-
sion; a high saturated fat (SFA) diet increases SREBF1
gene expression both in the liver and in pancreatic β-celled Central Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/4.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
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decreases SREBF1 gene expression [3,8,9]. The intake of
fish oil may have a favorable impact on insulin sensitivity.
Among fructose-induced hypertriglyceridemic and insulin
resistant male rhesus macaques, the intake of 4 g/day of
fish oil prevented the development of hypertriglyceridemia
and insulin resistance [10]. Studies observing rodents have
also observed a beneficial effect of fish oil on insulin sensi-
tivity [11,12]. In diet induced obese mice, the intake of
fish oil reduces SREBF1 gene expression levels in the
liver and modifies the expression of other genes in-
volved in lipid metabolism such as fatty acid synthase
gene (FASN) and acyl-Coenzyme A oxidase 1 (ACOX1)
[13]. Eicosapentaenoic acid (EPA) was shown to inhibit
SREBP-1 maturation [14] and to restore insulin secre-
tion after suppression by palmitate through an SREBP-
1c dependent mechanism [15].
The genetic variability within the SREBF1 gene may
play a role in insulin resistance or type 2 diabetes. A
meta-analysis of genome wide scans in European popu-
lations showed linkage with type 2 diabetes in the 17p11
region, which comprises the SREBF1 gene [16]. Single
nucleotide polymorphisms (SNPs) within the SREBF1
gene have been associated with type 2 diabetes, insulin
resistance, obesity and blood lipid levels [17-22]. Among
humans the impacts of fish oil on insulin sensitivity, glu-
cose concentrations and/or the risk of type 2 diabetes
have not been consistent [23-27]. Some studies even ob-
served an increase in fasting insulin concentrations and/
or fasting glucose concentrations [28,29]. These incon-
sistencies in results could be partly due to differences in
the genetic background, dietary intakes and/or lifestyle.
Our group previously observed a large inter-individual
variability in the response of insulin sensitivity to a fish oil
supplementation [30]. Thus, the objective of this study
was to examine the associations between SNPs within
SREBF1 gene and the plasma insulin and glucose response
to a fish oil supplementation.
Methods
Participants
Methods related to this study cohort have been previ-
ously described [31]. Briefly, a total of 254 unrelated par-
ticipants from the greater Quebec City metropolitan
area were recruited to participate in this clinical trial be-
tween September 2009 and December 2011 through ad-
vertisements in local newspapers as well as by electronic
messages sent to university students/employees. To be
eligible, participants had to be non-smokers and without
any thyroid or metabolic disorders requiring treatment,
for example diabetes, hypertension, severe dyslipidemia,
and/or coronary heart disease. A total of 210 partici-
pants completed the fish oil supplementation period.
However, fasting insulin and glucose concentrationswere obtained only for 207 participants. The experimen-
tal protocol was approved by the ethics committees of
Laval University Hospital Research Center and Laval
University. This clinical trial was registered at clinical-
trials.gov (NCT01343342). Informed written consent was
obtained from all the study participants.Study design and diets
The study design and diets have been described previ-
ously [31]. Briefly, participants followed a run-in period
of 2 weeks. Individual dietary instructions were given by
a trained dietitian to achieve the recommendations from
Canada’s Food Guide. After the 2-week run-in period,
each participant received a bottle containing fish oil cap-
sules for the next 6 weeks. They were instructed to take
five capsules (1 g of fish oil/capsule) per day (Ocean
Nutrition, Nova Scotia, Canada), providing a total of 5 g
of fish oil (1.9-2.2 g EPA and 1.1 g docosahexaenoic acid
(DHA)) per day. Compliance was assessed from the re-
turn of bottles and by measuring erythrocyte membranes
and plasma phospholipids fatty acid (FA) composition.
Dietary intakes were assessed at screening using a vali-
dated food frequency questionnaire (FFQ) [32]. Dietary in-
takes were also measured pre- and post-supplementation
using two 3-day dietary records.Biochemical parameters
The morning after a 12-hour overnight fast and 48-h alco-
hol abstinence, blood samples were collected from an
antecubital vein into vacutainer tubes containing EDTA.
Blood samples were collected at screening, baseline, pre-
supplementation (two weeks after baseline) and post-
supplementation (six weeks after pre-supplementation).
Plasma was separated by centrifugation (2500 × g for
10 minutes at 4°C), samples were aliquoted and frozen for
subsequent analyses. Plasma total cholesterol (total-C) and
plasma triglyceride concentrations were measured using
enzymatic assays [33,34]. Infranatant (d >1.006 g/ml) with
heparin-manganese chloride was used to precipitate VLDL
and LDL and then determine HDL-cholesterol concentra-
tions (HDL-C) [35]. The equation of Friedewald was used
to estimate LDL-cholesterol concentrations (LDL-C) [36].
Non-HDL-C was calculated by subtracting HDL-C from
total-C. Fasting insulin concentrations were measured
by radioimmunoassay with polyethylene glycol separ-
ation [37]. Fasting glucose concentrations were enzymati-
cally measured [38]. The quantitative insulin sensitivity
check index (QUICKI) was used as a marker of insulin
sensitivity calculated as follow: 1/(log(insulin(mU/L)) + log
(glucose (mg/dL))) [39]. QUICKI has been reported to be
more reproducible than the common homeostasis model
assessment (HOMA) of insulin resistance [40] and has a
strong linear correlation with glucose clamp estimates
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insulin resistance, diabetes and hypertension) [41].SNPs selection and genotyping
As described previously [31], SNPs were selected with the
International HapMap Project SNP database (HapMap
Data Rel 28 Phase II + III, August 10, on National Center
for Biotechnology Information (NCBI) B36 assembly,
dbSNP b126). Tag SNPs (tSNPs) were determined with
the tagger procedure in HaploView software version 4.2
with minor allele frequency (MAF) of >0.05 and pairwise
tagging r2 ≥ 0.80. Afterwards, as shown in Figure 1, linkage
disequilibrium (LD) plot were generated with Haploview
software version 4.2. Figure 1 also illustrates the high LD
between the chosen tSNP rs4925115 and the well de-
scribed rs2297508 located in exon 18c of SREBF1 gene
[17,20,21]. All tSNPs were genotyped within INAF labora-
tories with the TAQMAN methodology [42], as described
previously [43]. Briefly, genotypes were determined using
ABI Prism SDS version 2.0.5 (Applied Biosystem, Foster
City, CA, USA). All SNPs were successfully genotyped.Figure 1 Linkage disequilibrium (LD) plot of tSNPs within
SREBF1 gene. Figure legend. LD plots were generated by HaploView
software version 4.2 using r2 LD values. Two of the selected tSNPs
(rs12953299 and rs4925115 of the first cohort) were in moderate to
high LD with the exonic SNP rs2297508 (second cohort) (rs12953299
(r2 = 0.62) and rs4925115 (r2 = 0.95)).Fatty acid composition of erythrocyte membranes and
plasma phospholipids
As described previously [44], FA composition was mea-
sured in erythrocyte membranes by gas chromatographic
analysis in a subset of 31 participants. Methods to ex-
tract plasma phospholipids have been described else-
where [31]. FA composition from plasma phospholipids
were measured on the total cohort of 210 participants.
Briefly, plasma lipids were extracted according to a
modified Folch method [45]. Capillary gas chromatog-
raphy was used to obtain FA profiles [46]. FA profiles
both in erythrocyte membranes and plasma phospho-
lipids were expressed as the relative percentage areas of
total FAs.
Gene expression assessment
Blood samples (pre- and post- supplementation) were col-
lected into an 8-ml Cell Preparation Tube (CPT) (Becton
Dickinson, Oakville, On, Canada). Gene expression levels
were measured in peripheral blood mononuclear cells
(PBMCs), which are considered a valid proxy measure for
many tissues including the liver [47,48]. Peripheral blood
mononuclear cells (PBMCs) were separated by centrifuga-
tion (1500 × g, 20 min, at room temperature) and washed
according to the manufacturer’s instructions. Total RNA
was extracted with RNeasy Plus Mini Kit (QIAGEN,
Mississauga, On, Canada) according to manufacturer’s
protocol. Spectrophotometric quantification was rea-
lised with NanoDrop 2000C UV–vis Spectrophotometer
(Thermo Scientific) and cDNA was generated using
400 ng of total RNA with the High Capacity cDNA Re-
verse Transcription Kit (Life Technologies™). cDNA was
mixed with TaqMan OpenArray® Real-Time PCR Mas-
ter Mix (#4462164, Life Technologies™). The assays
used were as follows: Hs01088691_m1 (SREBF1) and
GAPDH Hs99999905_m1 as the housekeeping gene. All
assays used the same fluorescent reporter probe (FAM
dye labeled). All samples were run in triplicate on a
QuantStudio™ 12 K Flex Real-Time PCR (RT-PCR) System
(Life Technologies™) using 48-well plates TaqMan® Open-
Array® RT PCR Inventoried Format 18. The RT-PCR re-
sults were analysed with ExpressionSuite software v1.0.1
(Life Technologies™).
Second cohort
Seven hundred (700) Caucasians aged between 18 and
55 years were recruited in the Quebec City metropolitan
region. Recruitment occurred between 2004 and 2006
through public advertisements (local newspapers and
electronic messages) sent to university and hospital em-
ployees, as described previously [49]. A trained research
assistant took anthropometric measures. A registered
dietitian administered a validated FFQ to assess dietary in-
takes [32]. SREBF1 c.*619C >G (rs2297508) was genotyped
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were performed by using a model including the interaction
term SNP*PUFA with the GLM procedure in SAS and the
type 3 sum of squares for unbalanced study design. Age,
sex, BMI and total energy intakes were considered as con-
founding variables.
Statistical analyses
The Hardy-Weinberg equilibrium was tested with the
ALLELE procedure of SAS version 9.3 using Fisher’s
exact test (P < 0.01). When the genotype frequency for
homozygous individuals of the minor allele was <5%,
carriers (heterozygotes and homozygotes) of the minor
allele were grouped.
The sample size was calculated based on plasma trigly-
ceride changes following the fish oil supplementation
with a genetic variation occurring in a relatively low fre-
quency (5%) of the population. A group of 152 partici-
pants was sufficient to provide an 80% probability and a
5% significance level of detecting an anticipated differ-
ence of 0.25 mmol/L in plasma triglyceride concentra-
tions after 6 weeks of fish oil supplementation.
Non-normally distributed variables were logarithmic-
ally transformed. Fasting insulin concentration values
higher or lower than means ± 3 multiplied by standard
deviation (SD) were considered as outliers (n = 6), thus
201 participants were kept for the statistical analyses.
Differences were assessed using analyses of variance
(ANOVA) with the GLM procedure in SAS and the
type 3 sum of squares for unbalanced study design.
The fasting insulin response (delta) was calculated as
followed: ((post-supplementation insulin concentrations
minus pre-supplementation insulin concentrations)/
pre-supplementation insulin concentrations*100). The
same model was used to test the associations with fast-
ing glucose concentrations, insulin sensitivity (QUICKI)
and FA composition both in erythrocytes and plasma
phospholipid membranes. Each model was adjusted for
the effects of age, sex and BMI. To take into account
the impact of multiple testing, the simpleM method de-
scribed by Gao et al. [50] was utilised. Briefly, this
method considers the impacts of LD between SNPs and
has been demonstrated as efficient and accurate com-
paratively to permutation-based corrections [50]. First,
the composite LD correlation matrix was derived from
the data set. Then, eigenvalues were calculated using
the SAS PRINCOMP procedure and the number of ef-
fective independent tests was inferred so that the corre-
sponding eigenvalues explain 99.5% of the variation in
SNP data or the variables (fasting glucose, insulin and
QUICKI), as proposed by Gao et al. [50]. According to
Gao’s method, the number of effective independent tests
for the three SNPs was 2 and for the three traits (fasting
glucose, insulin and QUICKI) was 2. The final step appliesthe Bonferroni correction formula to calculate the ad-
justed point-wise significance level, which was defined as
αG = 0.05/(2X2) (effective independent tests). Thus, p-
values <0.0125 were considered significant (p = 0.05/(4)).
All statistical analyses were performed using SAS statistical
software version 9.3 (SAS Institute, Inc., Cary, NC, USA).
Results
All tSNPs were in Hardy-Weinberg equilibrium. Three
tSNPs covered 100% of the known genetic variability
within the SREBF1 gene [31]. As presented in Figure 1,
two of the selected tSNPs were in moderate to high LD
with the exonic SNP rs2297508 (rs12953299 (r2 = 0.62)
and rs4925115 (r2 = 0.95)).
Baseline characteristics of the study participants are
shown in Table 1. Before the fish oil supplementation
period, no differences in fasting insulin concentrations
according to genotypes were observed for the three
tSNPs (rs12953299, rs4925118 and rs4925115) (p = 0.29,
p = 0.20 and p = 0.70, respectively). Also there were no
differences in either fasting glucose concentrations ac-
cording to genotypes of rs12953299, rs4925118 and
rs4925115 (p = 0.16, p = 0.64 and p = 0.22, respectively)
or for insulin sensitivity (QUICKI) values (p = 0.20, p = 0.18
and p = 0.76, respectively).
Globally, during the study protocol fasting insulin con-
centrations were not modified (pre-supplementation insulin
concentrations: 77.7 ± 29.3pmol/L; post-supplementation
insulin concentrations: 79.0 ± 30.0pmol/L) (p = 0.52)). Fast-
ing glucose concentrations slightly increased from 4.95 ±
0.44 mmol/L to 5.04 ± 0.49 mmol/L after the fish oil sup-
plementation period (p = 0.0002), as previously reported
[51]. An important inter-individual variability has been
observed in the response of fasting insulin concentra-
tions, ranging from a decrease of −53.0% to an increase
of +135.2%. Briefly, 110 individuals decreased (relative
change ≤ 0%) and 91 increased (relative change > 0%)
their fasting insulin concentrations. Globally, the mean
change in insulin concentrations was 5.1% ± 30.0%. The
insulin sensitivity (QUICKI) was not modified by the
fish oil supplementation (p = 0.19).
No differences according to genotypes of the SREBF1
gene were observed in the response of fatty acid n-3
PUFA (EPA, DHA and total n-3 PUFA) phospholipid
content to the fish oil supplementation. A difference was
observed for EPA concentrations in erythrocyte mem-
branes according to rs4925118 genotypes (p = 0.02) for
which the relative increase following the fish oil supple-
mentation was greater among C/C homozygotes than
for the T allele carriers (T/T + C/T = 147.7 ± 80.0% (n = 4);
C/C = 236.5 ± 73.0% (n = 23)). A trend (p = 0.07) was also
observed for pre-supplementation EPA content in erythro-
cyte membranes according to rs4925118 genotypes (T/T +
C/T = 0.88 ± 0.33% (n = 4); C/C = 0.68 ± 0.22% (n = 24)).
Table 1 Descriptive characteristics at baseline, pre-supplementation and post-supplementation (n = 201)
Variables Means ± SD Pre-supplementation Post-supplementation P-value1
Age (years) 30.9 ± 8.7 - -
Sex (men/women) 92/109 - -
BMI (Kg/m2) 27.6 ± 3.5 27.6 ± 3.5 27.7 ± 3.6 0.03
Waist circumference (cm) Men: 94.5 ± 10.5 Men: 94.4 ± 10.3 Men: 94.8 ± 10.3 0.10
Women: 91.5 ± 10.2 Women: 91.5 ± 9.9 Women: 91.4 ± 10.2 0.65
Fasting glucose (mmol/L) 4.94 ± 0.53 4.95 ± 0.44 5.04 ± 0.49 0.0002
Fasting insulin (pmol/L) 79.0 ± 27.5 (n = 199) 77.7 ± 29.3 79.0 ± 30.0 0.52
QUICKI 0.367 ± 0.018 (n = 199) 0.338 ± 0.019 0.336 ± 0.020 0.19
HOMA-IR 2.51 ± 1.00 (n = 199) 2.48 ± 1.01 2.57 ± 1.06 0.12
Total-C (mmol/L) 4.80 ± 1.01 4.74 ± 0.90 4.71 ± 0.95 0.45
LDL-C (mmol/L) 2.78 ± 0.87 2.75 ± 0.81 2.77 ± 0.86 0.40
HDL-C (mmol/L) Men : 1.29 ± 0.31 Men : 1.29 ± 0.30 Men : 1.29 ± 0.33 0.72
Women : 1.61 ± 0.40 Women : 1.58 ± 0.36 Women : 1.64 ± 0.40 0.002
Triglycerides (mmol/L) 1.21 ± 0.60 1.19 ± 0.60 1.00 ± 0.46 <0.0001
Means ± SD.
1P-values were determined using a paired t-test and compared post-supplementation to pre-supplementation values.
QUICKI: quantitative insulin sensitivity check index; HOMA-IR: homeostasis model assessment insulin resistance.
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fish oil supplementation (p = 0.85). As shown in Table 2, no
differences were observed in the response of SREBF1 gene
expression levels to fish oil supplementation between geno-
types of rs4925118 and rs4925115 (p = 0.59, p = 0.47 and
p = 0.25, respectively).
As shown in Figure 2, the% change of fasting insulin con-
centrations ((post-supplementation insulin concentrations
minus pre-supplementation insulin concentrations)/pre-
supplementation insulin concentrations*100) following the
fish oil supplementation was different according to ge-
notypes of the three tSNPs (rs12953299, rs4925118 and
rs4925115) within the SREBF1 gene, adjusted for age,Table 2 Gene expression response according to
genotypes of SNPs within SREBF1 gene
SNPs Genotype Fold change1 P-value2
rs12953299 A/A (n = 45) 1.04 ± 0.36 0.59
A/G (n = 98) 1.05 ± 0.27
G/G (n = 55) 1.00 ± 0.22
rs4925118 T/T + C/T (n = 66) 1.06 ± 0.26 0.47
C/C (n = 132) 1.02 ± 0.29
rs4925115 A/A (n = 32) 1.00 ± 0.25 0.25
A/G (n = 103) 1.07 ± 0.32
G/G (n = 63) 1.00 ± 0.23
Means ± SD.
1The fold change represents post-supplementation relative gene expression
levels compared to pre-supplementation relative gene expression levels.
Fold change = 2−ΔΔCT = 2−(post-supplementation ΔCT-pre-supplementation ΔCT).
2P-values were calculated with an ANOVA adjusted for age, sex and BMI.
SNPs: single-nucleotide polymorphisms; SREBF1: sterol regulatory element binding
transcription factor 1.sex and BMI (p = 0.01, p = 0.005 and p = 0.004, respect-
ively). The response of fasting glucose concentrations
was not different according to genotypes of the tSNPs
(rs12953299, rs4925118 and rs4925115). The insulin
sensitivity (QUICKI) was associated with the tSNPs
rs12953299 and rs4925115 (p = 0.009 and p = 0.01, re-
spectively) but not with rs4925118 (p = 0.16). The po-
tential effects of total dietary n-3 PUFA intakes in the
participants’ habitual diets were included as a con-
founding variable in these models and did not modify
the associations observed (data not shown).Second cohort
As presented in Table 3, one significant gene-diet inter-
action effects on QUICKI (insulin sensitivity index) was
observed between rs2297508 and dietary PUFA intakes
(in grams) (p = 0.05). To further understand these asso-
ciations dietary PUFA intakes were divided in tertiles.
Figure 3 presents QUICKI values according to genotype
of rs2297508 and tertiles of dietary PUFA intakes. A sig-
nificant difference was observed only among C/C homo-
zygotes for which individuals with the highest dietary
PUFA intakes had higher QUICKI values than individ-
uals with the lowest dietary PUFA intakes (p = 0.03). A
trend (p = 0.06) was observed for the interaction effect
on QUICKI between rs2297508 and dietary intakes of
omega-3 PUFA (in grams). Both models were adjusted
for the effects of age, sex, BMI and energy intakes.
Genotype of rs2297508 alone was not associated with
QUICKI values (p = 0.21). No gene-diet interaction effects
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Figure 2 The relative response in fasting insulin concentrations
and QUICKI index (insulin sensitivity) according to genotype.
Figure legend. a) rs12953299 (A/A: n = 46, A/G: n = 100, G/G: n = 55);
Delta insulin (A/A: 15.3 ± 32.0%, A/G: 1.2 ± 30.1%, G/G: 3.9 ± 26.4%),
P-value for delta insulin model: p = 0.01; Delta QUICKI (A/A: −2.0 ±
4.1%, A/G: 0.4 ± 4.8%, G/G: 3.9 ± 26.4%), P-value for delta QUICKI
model: p = 0.009 b) rs4925118 (T/T + C/T: n = 67, C/C: n = 134); Delta
insulin (T/T + C/T: 14.1 ± 36.2%, C/C: 0.6 ± 25.3%), P-value for delta
insulin model: p = 0.005; P-value for delta QUICKI model: p = 0.16 c)
rs4925115 (A/A: n = 33, A/G: n = 105, G/G: n = 63); Delta insulin (A/A:
19.5 ± 34.0%, A/G: 3.4 ± 29.3%, G/G: 0.6 ± 27.0%), P-value for delta
insulin model: p = 0.004; Delta QUICKI (A/A: −2.3 ± 4.2%, A/G: −0.1 ±
4.5%, 0.4 ± 4.5%), P-value for delta QUICKI model: p = 0.01. Delta
values (relative change) were calculated as ((post-supplementation
values minus pre-supplementation values)/pre-supplementation
values*100). All differences were assessed with ANOVA adjusted for
age, sex and BMI. Means ± SE.
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Participants of this cohort were overweight but generally
considered as healthy according to lipid concentration
values [52]. Fasting glucose concentrations were within
normal values [53]. The QUICKI index indicated aprobable borderline insulin resistance state among these
participants [39,41,54]. An important inter-individual
variability in the response of fasting insulin concentra-
tions was observed. This wide inter-individual variability
in HOMA-insulin sensitivity (IS) response in this cohort
has been previously described [30]. In this study, effects
of tSNPs within the SREBF1 gene on the fasting insulin
and insulin sensitivity responses were observed after the
fish oil supplementation.
SREBF1 gene is an important transcription factor
regulating many genes involved in lipid metabolism and
also in insulin induced glucose metabolism [1]. More-
over, the expression of SREBF1 gene is significantly af-
fected by dietary intakes, including fish oil [3,6-9,13].
Therefore, SREBF1 gene is an interesting candidate for
the study of inter-individual variability in the response of
fasting insulin concentrations to a fish oil supplementa-
tion. Whether these impacts are mediated through the
effects of SREBP-1c within hepatocytes and/or pancre-
atic cells is unknown. In the liver, increased SREBP-1c
concentrations have been shown to repress the tran-
scription of insulin receptor substrate 2 (IRS2) gene
which led to a detrimental impact on insulin sensitivity,
a fatty liver and a production of VLDL enriched in tri-
glycerides [55]. IRS2 mediates insulin signaling in the
liver [55]. Insulin in the liver activates glycogen synthesis,
inhibits hepatic glucose output and promotes lipogenesis
[55]. The induction of SREBP-1c in mice resulted in im-
paired secretion and glucose intolerance, as reviewed by
Shimano et al. [3]. SREBP-1c may also affect insulin secre-
tion of pancreatic β-cell through a mechanism involving
uncoupling protein-2 (UCP2) [56]. A sterol regulatory
element (SRE) has been discovered in the promoter region
of UCP2 gene [56]. An increase in UCP2 gene expression
is associated with a lower efficacy of glucose-induced insu-
lin secretion [57]. In the present study no differences in
SREBF1 gene expression were observed following the fish
oil supplementation. Studies examining the impacts of
PUFA, fish oil or EPA on SREBF1 gene regulation have
been conducted among mice or in vitro with human cells
[6-9,13-15]. It is possible that the dose used for the sup-
plementation in this study was insufficient to observe an
effect on SREBF1 gene expression. However, the activity
of lipogenic target genes of SREBP-1c transcription factor
is not only regulated by SREBF1 mRNA abundance. For
example, Tanaka et al. [14] did not observe reduced
SREBF1 mRNA levels but rather an inhibition of the
maturation of SREBP-1c. Thus, the fish oil supplemen-
tation in the present study may have had effects on the
insulin response through posttranslational modifica-
tions of SREBP-1c and its impact on subsequent target
genes. However, we cannot rule out the possibility that
significant differences may have been observed if expres-
sion levels were directly measured in hepatocytes [58].
Table 3 Gene-diet interaction effects on QUICKI between rs2297508 and PUFA intakes (total and n-3 PUFA)
Dietary n-3 PUFA intake (in grams) Dietary PUFA intake (in grams)
Genotype β (Interaction term) P Interaction effect1 β (Interaction term) P Interaction effect1
G/G (n = 125) −0.0194 ± 0.0083 0.06 −0.0163 ± 0.0067 0.05
C/G (n = 297) −0.0073 ± 0.0064 −0.0073 ± 0.0052
C/C (n = 242) 0 0
Means ± SD.
1ANOVA adjusted for age, sex, BMI and energy intakes considering the interaction effect between genotype and dietary fat intakes.
PUFA: polyunsaturated fatty acid.
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http://www.lipidworld.com/content/13/1/152The overall effects of fish oil intakes on insulin resist-
ance, glycemic control and the risk of type 2 diabetes ap-
pears to be negligible, as recently reviewed by Wu et al.
[59]. However, the authors observed a large heterogen-
eity. Thus, it is possible that for some individuals the im-
pacts of fish oil intake on the risk of type 2 diabetes or
other related biologic parameters may be beneficial and
for some other individuals detrimental. Quite a few stud-
ies have observed a modest increase in fasting glucose
concentrations after fish oil intake [60]. It has been ob-
served that the reduction in plasma triglyceride concen-
trations induced by n-3 PUFA intake may be partly
induced by the increased use of glycerol for gluconeo-
genesis which may explain increases in fasting glucose
concentrations [61,62]. The increase in fasting glucose
concentrations was also observed in this cohort [51].
However, because this study was designed without a
control group, we cannot rule out the possibility that
part of these changes may be related to modifications in
the participants’ lifestyle during the protocol. Still, par-
ticipants were asked to maintain their nutritional and
physical activity habits stable during the intervention.

























Figure 3 QUICKI index values according to rs2297508 genotype
and tertiles of dietary PUFA intakes. Figure legend. Tertile 1 of
dietary PUFA intakes (3.17 g-11.97 g) (G/G: n = 48; C/G: n = 95; C/C:
n = 67), Tertile 2 of dietary PUFA intakes (11.98 g-16.49 g) (G/G: n = 41;
C/G: n = 91; C/C: n = 82) and Tertile 3 of dietary PUFA intakes (16.53
g-48.18 g) (G/G: n = 27; C/G: n = 96; C/C: n = 86). Differences in QUICKI
values between tertiles were assessed with an ANOVA by genotype
adjusted for the effects of age, sex and BMI. Means with different
letters are significantly different. Means ± SE.during the study protocol revealed that they were quite
stable (data not shown).
In the present study, homozygotes for minor alleles of
the tSNPs rs12953299 and rs4925115 were associated
with an increase in fasting insulin concentrations and a
decrease in insulin sensitivity assessed by QUICKI after
a fish oil supplementation compared to the other geno-
types. For the tSNP rs4925118 only a difference in the
fasting insulin response was observed, carriers of the T
allele increased their fasting insulin concentrations after
a fish oil supplementation compared to C/C homozy-
gotes. Thus, for these genotypes the impact of fish oil on
insulin sensitivity may be detrimental. For the other ge-
notypes, the fish oil supplementation had a minor im-
pact which may be less likely to increase the risk of type
2 diabetes. The genetic variability within transcription
factors such as the SREBF1 gene, which are affected by
fish oil intake may be the key to understanding the vari-
ability observed in the response of fasting insulin con-
centrations and insulin sensitivity [63]. SNPs within the
SREBF1 gene have been frequently associated with type
2 diabetes or insulin resistance. A meta-analysis of four
European genome screens found the strongest linkage
with type 2 diabetes on chromosome 17p11.2-q22 where
is located the SREBF1 gene [16]. One SNP (rs2297508)
within SREBF1 gene has been reported across a few pop-
ulations to be associated with the risk of type 2 diabetes
[17,18,20,21]. Felder et al. [21] found that the C/G and
the G/G genotypes of rs2297508 had a ~1.4-fold higher
risk of type 2 diabetes. In a French cohort, rs2297508
was also associated with obesity and type 2 diabetes in-
dependently of the obesity status [17]. Moreover, the
SNP rs2297508 was related to sex-specific differences in
the response of lipid and insulin concentrations as well
as in HOMA-IR to a diet high in carbohydrates [64]. In
their study, Zhang et al. [64] observed that the C allele
of rs2297508 was associated with more favorable im-
pacts on plasma triglyceride, fasting insulin and HOMA-
IR than the G allele. In our study, the genotype alone
was not associated with QUICKI values. However, a
gene-diet interaction effect between rs2297508 and diet-
ary PUFA intakes was observed. A large-scale gene-
centric meta-analysis identified the SREBF1 gene as a
type 2 diabetes loci among Europeans, with rs4925115
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http://www.lipidworld.com/content/13/1/152being the most significantly associated SNP [19]. The
three tSNPs (rs12953299, rs4925115 and rs4925118)
covered 100% of the known genetic variability within the
SREBF1 gene. However, two of these tSNPs were in
moderate LD (rs12953299 and rs4925115, r2 = 0.68) and
were also in moderate to high LD with the most studied
SREBF1 gene SNP rs2297508 (r2 = 0.62 and r2 = 0.95, re-
spectively). Since SNPs within the SREBF1 gene includ-
ing the promoter region, are in moderate to high LD, we
cannot rule out the possibility that the tSNPs examined
herein may also be in LD with SNPs within the SREBF1
gene promoter region which could affect its expression
[65]. In the second cohort, the SNP rs2297508 from
SREBF1 gene interacted with dietary PUFA intakes to
affect insulin sensitivity (assessed by QUICKI). This SNP
is located in exon 18c and is synonymous (Gly952Gly).
Thus, these results may indicate that the genetic vari-
ability within the SREBF1 gene has an impact on the re-
sponse of insulin sensitivity to n-3 PUFA and/or PUFA
intakes.
Conclusion
To our knowledge this study was the first to examine as-
sociations between SNPs within the SREBF1 gene and
the response of fasting insulin and insulin sensitivity to a
fish oil supplementation. In this study, the genetic vari-
ability within the SREBF1 gene was associated with dif-
ferences in the response of insulin and insulin sensitivity
to a fish oil supplementation. SREBF1 gene may be an
important candidate to study in order to understand the
discrepancies observed in the impacts of fish oil on insu-
lin resistance. Clinical trials taking into account the gen-
etic variability within the SREBF1 gene and observing
the impact of fish oil supplementation on insulin and in-
sulin sensitivity are warranted. Moreover, the identifica-
tion of individuals with a beneficial or adverse response
to fish oil is important in order to appropriately recom-
mend its supplementation.
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